Tag: cancer
Study looks at Efficacy and Metabolism of Azonafide-based ADCs in Microgravity
A new study is investigating the efficacy and metabolism of azonafide-based antibody-drug conjugates (ADCs) in microgravity. The investigators seeks to activate immunogenic cell death...
What Governments Can Do To Address Cancer
While much work remains to find a cure for cancer – the good news is we know that many forms of cancer are preventable....
To Reimburse or not to Reimburse – That is the Question
Novel, innovative (bio)pharmaceutical drugs are an important part of our global healthcare system, offering advanced, radical new personalized and targeted therapy options to patients...
Antibody-drug conjugates: Recent Advances in Conjugation and Linker Chemistries
Authors: Tsuchikama K , An Z
Title: Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Published in: Protein Cell. 2016 Oct 14.
Keywords: antibody-drug conjugates; cancer;...
Outsmarting Cancer – From the War on Cancer to the Cancer...
On May 25, 1961, President John F. Kennedy announced, before a special joint session of congress, the dramatic and ambitious goal of sending a...
Enhancing Activity of Sacituzumab Govitecan in SN-38-Resistant Cancer
Adding an inhibitor of ATP-binding cassette (ABC) transporters to sacituzumab govitecan increased the median survival of mice bearing a SN-38-resistant human gastric cancer cell...
Strategies of Targeting the Extracellular Domain of RON Tyrosine Kinase Receptor...
Authors: Zarei O, Benvenuti S, Ustun-Alkan F, Hamzeh-Mivehroud M, Dastmalchi S.
Title: Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer...
Avacta and Glythera Partner to Develop Novel, Highly Targeted, Drugs
Avacta Life Sciences, the developer of Affimer® biotherapeutics and research reagents will collaborate with Glythera a developer of advanced, stable conjugation chemistries and novel, ultra-potent...
Early Detection: The New Cancer Paradigm
A seemingly healthy patient walks into the doctor’s office for a routine checkup. The doctor says: "I have good news and bad news. The...
Sneaking Medicines Across the Blood-Brain Barrier
Research published in the November 2014 edition of The FASEB Journal, published by the Federation of the American Societies for Experimental Biology, suggests that a very small single domain antibody called FC5 has proven able to cross the blood-brain barrier (BBB). This opens the door to new treatments for a multitude of brain diseases.
